Spondyloarthritis & psoriatic arthritis
Thresholds for efficacy outcomes in psoriatic arthritis vary according to baseline disease activity but not according to prior tumour necrosis factor inhibitor treatment
Authors' conclusion
Estimated MCII thresholds were consistent regardless of prior TNFi but greater for participants with higher baseline joint disease activity, indicating disease severity may impact perceived PsA improvement.
Study context
- Population
- Participants with active psoriatic arthritis (PsA) in 3 randomised clinical trials (RCTs), subgroups by prior tumour necrosis factor inhibitor (TNFi) treatment and baseline cDAPSA and PASDAS disease activity3 RCTs
- Comparison
- Minimal clinically important improvement (MCII) thresholds by prior TNFi treatment (TNFi-experienced vs biologic-naïve) and by baseline disease activity (high vs moderate); guselkumab Q8W vs placebo
- Outcome
- MCII thresholds for cDAPSA, PASDAS and patient-reported assessments of arthritis and psoriasis, pain, fatigue and physical function
Methodological detailsdistribution-based methods, subgroup analysis
- Distribution-based methods
- Subgroup analysis
Pooled result
As reported in the abstract
MCII thresholds by subgroup
- MCII thresholds for all examined measures consistent across TNFi-experienced and biologic-naïve cohorts
- cDAPSA, but not PASDAS, MCII more stringent with high vs moderate baseline disease activity
- Post hoc analysis
Further pooled results
Achievement of MCII thresholds, guselkumab vs placebo · as early as W8
- Greater odds of achieving MCII thresholds with guselkumab vs placebo, irrespective of prior TNFi and baseline cDAPSA and PASDAS disease activity
Original publication
Thresholds for efficacy outcomes in psoriatic arthritis vary according to baseline disease activity but not according to prior tumour necrosis factor inhibitor treatment. Ann Rheum Dis. Published 13 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →